ClinicaliQ Trial Snapshot
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) — Recruiting • Phase I • Oncology • NCT06637423.
- Drug being tested: Sacituzumab Tirumotecan (MK-2870), an antibody-drug conjugate targeting Trop-2, administered directly into the bladder to determine safety, tolerability, and maximum tolerated dose in bladder cancer patients.
- Patient eligibility overview: The trial enrolls patients with bladder cancer; specific eligibility criteria (disease stage, prior treatments, performance status) determine which patients can participate in this dose-escalation study.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.
Eligibility Snapshot
- : The key inclusion criteria include but are not limited to the following: * Has recurrent low-grade (Ta) Non-Muscle Invasive Bladder Cancer (NMIBC) in the bladder * Must have visible tumor by cystoscopy within 12 weeks prior to first dose * Has intermediate-risk NMIBC defined as 1 or more of the following risk factors: * Multiple tumors * >1 occurrence of low-grade NMIBC within 1 year of the current diagnosis at Screening * Early recurrence (3 cm * Failure of prior intravesical treatment * An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 14 days prior to first dose
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.